Reinvigorating the immune system to fight cancer with NM21-1480, a next generation IO drug in clinical development.

Developing the best MATCH for patients through plug & play assembly of novel multispecific biotherapeutics.

Advancing a proprietary pipeline of next generation immunology and immuno-oncology drugs.

numab graphic numab graphic numab graphic numab graphic

Highlights of our tech platform & competitive edge

Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first-generation antibody therapies in terms of potency, stability, effect duration, and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.

Enabling novel modes of action with favorable benefit-to-risk profiles

We are establishing a proprietary pipeline of differentiated therapeutics by targeting clinically validated pathways with multispecific molecules to create novel mechanisms of action designed to differentiate from standard of care by superior efficacy and favorable safety. Our most advanced program, ND021, exemplifies this strategy by blocking immune-suppressive PD-(L)1 signaling with best-in-class potency and simultaneously triggering 4-1BB-mediated T cell stimulation specifically in the tumor microenvironment. ND021 is about to enter Phase 1 clinical testing.



Latest News
September 30, 2020

Numab Therapeutics Appoints Daniel Vasella as new Chairman of the Board

Numab Therapeutics AG announced today the appointment of Dr. med.…

Numab Therapeutics AG announced today the appointment of Dr. med. Daniel Vasella, former Chairman and Chief Executive Officer of Novartis AG, as the new and independent Chairman of the Board of Numab. Dr. Vasella succeeds Dr. Oliver Middendorp, founder and current Chief Business Officer, who remains on the Board of Directors as a regular member.
August 24, 2020

Numab Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of ND021 Program

Numab Therapeutics AG announced today the first patient has been…

Numab Therapeutics AG announced today the first patient has been dosed in its proprietary ND021 program, a next-generation tri-specific immuno-oncology approach targeting PD-L1, 4-1BB and Serum Albumin. The study will initially enroll up to 102 cancer patients at four major clinical sites across the United States and Taiwan and will expand to additional centers as the study progresses. In its first part, this international, multi-center Phase 1/2 clinical study will investigate the safety and tolerability of ascending doses of NM21-1480, the company’s clinical lead molecule in the ND021 program, in patients with various forms of solid tumors and establish a recommended dose for continued clinical development. The trial will subsequently explore the anti-tumor activity of the compound in patients suffering from selected tumor types.  
July 07, 2020

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Numab Therapeutics and Boehringer Ingelheim today announced that…

Numab Therapeutics and Boehringer Ingelheim today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life-changing breakthrough therapies with Numab’s multi-specific antibody platform.   Lung and GI cancers and retinal diseases are key focus areas of Boehringer Ingelheim’s research and development program. In oncology the company has built a broad and diverse pipeline, combining cancer immunology and cancer cell-directed approaches. The novel T-cell engager to be developed with Numab adds to Boehringer Ingelheim’s growing cancer immunology portfolio and supports the strategy to take cancer on by targeting ‘cold’ tumors with synergistic combination approaches. In retinal diseases, Boehringer Ingelheim is pursuing a holistic approach leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases. The new GA program with Numab further broadens the company’s comprehensive portfolio of next-generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.
More News

Newsletter Sign Up

Our websites uses Google Analytics and cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our privacy statement.